PMID- 27894787
OWN - NLM
STAT- MEDLINE
DCOM- 20170615
LR  - 20181202
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 69
IP  - 3
DP  - 2017 Mar
TI  - Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients 
      after acute myocardial infarction: A non-randomized interventional pilot trial.
PG  - 511-517
LID - S0914-5087(16)30268-4 [pii]
LID - 10.1016/j.jjcc.2016.10.009 [doi]
AB  - BACKGROUND: Glucagon-like peptide 1 analogs are expected to exert a 
      cardio-protective action due to their effective glucose-lowering action and 
      favorable potency on multifactorial metabolic pathways. However, the safety and 
      tolerability of liraglutide treatment after a recent acute coronary syndrome 
      (ACS) in Japanese patients with type 2 diabetes mellitus (T2DM) have yet to be 
      fully established. METHODS: A total of eight T2DM patients were recruited within 
      2 weeks after the onset of a ST-elevation myocardial infarction (STEMI) followed 
      by successful percutaneous coronary intervention (PCI). The patients continued to 
      receive liraglutide (up to 0.9mg once daily) for 24 weeks after the ACS combined 
      with standard treatment such as a statin or beta-blocker. Changes in various 
      metabolic parameters from pre-liraglutide treatment values were evaluated 24 
      weeks after liraglutide treatment, and included glycemic and lipid profiles, and 
      cardiac systolic and diastolic function assessed by cardiac ultrasonography. 
      RESULTS: Twenty-four weeks of treatment with liraglutide reduced body weight 
      (67.0+/-5.8kg to 62.0+/-7.8kg, p=0.003) and HbA1c level (6.6+/-0.5% to 5.9+/-0.5%, 
      p=0.006) and increased the level of 1,5-anhydroglucitol (12.8+/-6.9mug/mL to 
      18.7+/-8.2mug/mL, p=0.008) without development of hypoglycemia. There were no 
      significant changes over 24 weeks in left ventricular systolic or diastolic 
      function assessed by cardiac ultrasonography. No participant developed a major 
      adverse cardiac event during the 24 weeks of liraglutide treatment, defined as 
      cardiac death, new onset or recurrence of myocardial infarction, or needing 
      target lesion revascularization. CONCLUSIONS: The present trial demonstrated that 
      liraglutide treatment after onset of STEMI was well-tolerated in Japanese 
      patients with T2DM over 24 weeks, and provided the first evidence to support 
      clinical application of liraglutide treatment even just after ACS in Japanese 
      high-risk T2DM patients.
CI  - Copyright (c) 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Kajiwara, Masataka
AU  - Kajiwara M
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Tanaka, Atsushi
AU  - Tanaka A
AD  - Department of Cardiovascular Medicine, Saga University, Saga, Japan.
FAU - Kawasaki, Tomohiro
AU  - Kawasaki T
AD  - Department of Cardiology, Cardiovascular Center, Shin-Koga Hospital, Kurume, 
      Japan.
FAU - Nakao, Koichi
AU  - Nakao K
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Sakamoto, Tomohiro
AU  - Sakamoto T
AD  - Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, 
      Kumamoto, Japan.
FAU - Toyoda, Shigeru
AU  - Toyoda S
AD  - Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, 
      Japan.
FAU - Inoue, Teruo
AU  - Inoue T
AD  - Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, 
      Japan.
FAU - Koga, Nobuhiko
AU  - Koga N
AD  - Department of Cardiology, Cardiovascular Center, Shin-Koga Hospital, Kurume, 
      Japan.
FAU - Node, Koichi
AU  - Node K
AD  - Department of Cardiovascular Medicine, Saga University, Saga, Japan. Electronic 
      address: node@cc.saga-u.ac.jp.
LA  - eng
SI  - UMIN-CTR/UMIN000006817
PT  - Journal Article
DEP - 20161125
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipids)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*complications/*drug therapy
MH  - Drug Administration Schedule
MH  - Echocardiography
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/*therapeutic use
MH  - Lipids/blood
MH  - Liraglutide/*adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*complications/diagnostic imaging/surgery
MH  - Percutaneous Coronary Intervention
MH  - Pilot Projects
MH  - Prospective Studies
OTO - NOTNLM
OT  - Cardiac function
OT  - Cardiac ultrasonography
OT  - Glucagon-like peptide 1 analog
OT  - Liraglutide
OT  - Type 2 diabetes mellitus
EDAT- 2016/11/30 06:00
MHDA- 2017/06/16 06:00
CRDT- 2016/11/30 06:00
PHST- 2016/09/08 00:00 [received]
PHST- 2016/10/07 00:00 [revised]
PHST- 2016/10/18 00:00 [accepted]
PHST- 2016/11/30 06:00 [pubmed]
PHST- 2017/06/16 06:00 [medline]
PHST- 2016/11/30 06:00 [entrez]
AID - S0914-5087(16)30268-4 [pii]
AID - 10.1016/j.jjcc.2016.10.009 [doi]
PST - ppublish
SO  - J Cardiol. 2017 Mar;69(3):511-517. doi: 10.1016/j.jjcc.2016.10.009. Epub 2016 Nov 
      25.